Removal of Warnings on HRT Products Announced
The Secretary of Health and Human Services, Robert F. Kennedy Jr., declared on Monday that the black box warnings associated with estrogen-based hormone replacement therapy (HRT) for women will be eliminated.
“For over two decades, American medical institutions have turned their backs on women,” Kennedy stated during a press conference at HHS headquarters. He expressed that millions have been made to fear a therapy that could provide them strength and dignity during challenging stages like menopause.
“That changes today,” he insisted, announcing that the FDA will start to lift the extensive warnings related to HRT products aimed at easing menopausal symptoms.
Present at the announcement were Kennedy’s wife, actress Cheryl Hines, as well as his daughters and second lady Usha Vance.
Both Kennedy and FDA Commissioner Marty McCulley referenced findings from over 20 years ago, backed by the National Institutes of Health’s Women’s Health Initiative, which suggested that HRT might expedite the development of existing breast cancer in women.
“The Women’s Health Initiative study was the largest in U.S. history, costing around $1 billion, but its findings have been misrepresented, creating lasting fear,” McCulley remarked. He added that any increase in breast cancer rates lacks statistical significance, emphasizing that without solid statistics, there’s no scientific basis for concern.
Kennedy added, “HRT has restored marriages, lifted women from depression, and kept families intact.”
McCulley clarified that this latest measure includes both bioidentical and synthetic hormones, indicating that the choice will rest with individual patients and their healthcare providers.
Urologist Kelly Casperson spoke at the event, presenting data that showed 30 percent of women forgo HRT due to the intimidating black box label.
This announcement has received positive reactions from various women’s health organizations. Stephen J. Fleischman, President of the American College of Obstetricians and Gynecologists, commented on the long-awaited changes to the warnings, stating they reflect the hard work of both physicians and patients nationwide.
Fleischman also mentioned that his organization advocates for removing black box labels on low-dose vaginal estrogens due to their minimal use among those suffering from menopausal symptoms.
“Today’s decision corrects the imbalance in women’s health policy,” remarked Monique Yohanan, a senior health policy fellow at the nonprofit Independent Women. She pointed out that currently, fewer than 5 percent of postmenopausal American women utilize menopausal hormone therapy, a significant drop from 25 to 30 percent two decades ago.
“By aligning the labeling with current evidence, the FDA is providing clarity for doctors and women, ensuring they can make informed choices,” Yohanan concluded.
